Big pharma investment in gene therapy

Facebook Twitter LinkedIn. The challenge for investors is that its lead XLMTM product has smaller commercial potential than other gene therapies, with fewer than babies born with it in the U. A risk with Regenxbio is the expiration of some patents on its vectors in the early s. Directory of sites. Drugmakers say building their own manufacturing plants is a response to rising costs and delays associated with relying on third-party contract manufacturers, which are also expanding to capitalize on demand. Google Firefox.

This copy is for your personal, non-commercial use. Big Pharma has been struggling for years to produce drugs that are major breakthroughs in medicine. For these companies, gene therapy may be the promised land. Gene therapy— treatments designed to replace faulty genes with healthy oharma —offers potential cures for hundreds of genetic diseases, like hemophilia and muscular dystrophy. That promise, and its rich commercial potential, has led to a land grab among the drug giants. Gene therapy is growing up as a business, but the science is decades old. More treatments could be approved in coming years.

Public enterprises minister is perhaps unable to truly reckon with the crisis he is tasked with solving. More and more people are finding that a well-balanced vegan diet has major health benefits, writes Sophie Medlin. Gene therapies aim to correct certain diseases by replacing the missing or mutated version of a gene found in a patient’s cells with healthy copies. But the treatments are also extremely complex to make, involving the cultivation of living material, and still pose a risk of serious side effects. Drugmakers say building their own manufacturing plants is a response to rising costs and delays associated with relying on third-party contract manufacturers, which are also expanding to capitalise on demand.

Data Policy. Keep me signed in. Recognizing that gene therapy could help all boys with DMD, the company moved to develop a treatment that could cannibalize its existing drugs. JMP Securities analyst Liisa Bayko sees a large opportunity for Sarepta in Duchenne muscular dystrophy because there are an estimated 70, patients globally, including more than 10, big pharma investment in gene therapy the U. Carl O’DonnellTamara Mathias. Your Ad Choices. Discover Thomson Reuters. Gbola Amusa, an analyst with Chardan Capital Markets, sees continued takeover activity in the sector and views uniQure as a leading candidate.